Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Liabilities (2017 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $848000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $848000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $848000.0, a N/A change, with the full-year FY2024 number at $3.8 million, down 40.01% from a year prior.
  • Other Non-Current Liabilities was $848000.0 for Q3 2025 at Cartesian Therapeutics, down from $2.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $45.5 million in Q1 2021 to a low of $848000.0 in Q3 2025.
  • A 5-year average of $18.3 million and a median of $13.1 million in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 66.59% in 2023, then crashed 40.01% in 2024.
  • Cartesian Therapeutics' Other Non-Current Liabilities stood at $40.6 million in 2021, then tumbled by 52.9% to $19.1 million in 2022, then crashed by 66.59% to $6.4 million in 2023, then plummeted by 40.01% to $3.8 million in 2024, then plummeted by 77.89% to $848000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Other Non-Current Liabilities are $848000.0 (Q3 2025), $2.0 million (Q1 2025), and $3.8 million (Q4 2024).